Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Neurotherapeutics |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1878747925001539 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849405696001441792 |
|---|---|
| author | Michal Geva Y Paul Goldberg Melanie L. Leitner Kelly Chen Wei Feng Noga Gershoni Emek James D. Berry Sabrina Paganoni Jeremy Shefner Merit ECudkowicz Michael R. Hayden |
| author_facet | Michal Geva Y Paul Goldberg Melanie L. Leitner Kelly Chen Wei Feng Noga Gershoni Emek James D. Berry Sabrina Paganoni Jeremy Shefner Merit ECudkowicz Michael R. Hayden |
| author_sort | Michal Geva |
| collection | DOAJ |
| format | Article |
| id | doaj-art-aef4d51aa334474a98becc4453b48776 |
| institution | Kabale University |
| issn | 1878-7479 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurotherapeutics |
| spelling | doaj-art-aef4d51aa334474a98becc4453b487762025-08-20T03:36:35ZengElsevierNeurotherapeutics1878-74792025-07-01224e0067510.1016/j.neurot.2025.e00675Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform TrialMichal Geva0Y Paul Goldberg1Melanie L. Leitner2Kelly Chen3Wei Feng4Noga Gershoni Emek5James D. Berry6Sabrina Paganoni7Jeremy Shefner8Merit ECudkowicz9Michael R. Hayden10Prilenia Therapeutics B.V.Prilenia Therapeutics B.V.Accelerating NeuroVentures, LLCPrilenia Therapeutics B.V.Prilenia Therapeutics B.V.Prilenia Therapeutics B.V.Sean M. Healey & AMG Center for ALS and Neurological Clinical Research Institute at Massachusetts General Hospital, Harvard Medical SchoolSean M. Healey & AMG Center for ALS and Neurological Clinical Research Institute at Massachusetts General Hospital, Harvard Medical SchoolBarrow Neurological InstituteSean M. Healey & AMG Center for ALS and Neurological Clinical Research Institute at Massachusetts General Hospital, Harvard Medical SchoolPrilenia Therapeutics B.V.http://www.sciencedirect.com/science/article/pii/S1878747925001539 |
| spellingShingle | Michal Geva Y Paul Goldberg Melanie L. Leitner Kelly Chen Wei Feng Noga Gershoni Emek James D. Berry Sabrina Paganoni Jeremy Shefner Merit ECudkowicz Michael R. Hayden Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial Neurotherapeutics |
| title | Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial |
| title_full | Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial |
| title_fullStr | Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial |
| title_full_unstemmed | Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial |
| title_short | Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial |
| title_sort | pridopidine treatment benefits in definite probable and early 18mo onset subjects with als in the healey als platform trial |
| url | http://www.sciencedirect.com/science/article/pii/S1878747925001539 |
| work_keys_str_mv | AT michalgeva pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial AT ypaulgoldberg pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial AT melanielleitner pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial AT kellychen pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial AT weifeng pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial AT nogagershoniemek pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial AT jamesdberry pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial AT sabrinapaganoni pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial AT jeremyshefner pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial AT meritecudkowicz pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial AT michaelrhayden pridopidinetreatmentbenefitsindefiniteprobableandearly18moonsetsubjectswithalsinthehealeyalsplatformtrial |